| Title: | Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer |
| Author(s): | Erickson BK; Kinde I; Dobbin ZC; Wang Y; Martin JY; Alvarez RD; Conner MG; Huh WK; Roden RBS; Kinzler KW; Papadopoulos N; Vogelstein B; Diaz LA; Landen CN; |
| Address: | "Departments of Obstetrics and Gynecology and Pathology, University of Alabama at Birmingham, Birmingham, Alabama; the Ludwig Center of Cancer Genetics and Therapeutics and the Swim Across America Laboratory at Johns Hopkins University, Baltimore, Maryland; and the Departments of Obstetrics and Gynecology and Pathology, University of Virginia, Charlottesville, Virginia" |
| DOI: | 10.1097/AOG.0000000000000484 |
| ISSN/ISBN: | 1873-233X (Electronic) 0029-7844 (Print) 0029-7844 (Linking) |
| Abstract: | "OBJECTIVE: To investigate whether tumor cells could be detected in the vagina of women with serous ovarian cancer through TP53 analysis of DNA samples collected by placement of a vaginal tampon. METHODS: Women undergoing surgery for a pelvic mass were identified in the gynecologic oncology clinic. They placed a vaginal tampon before surgery, which was removed in the operating room. Cells were isolated and DNA was extracted from both the cells trapped within the tampon and the primary tumor. In patients with serous carcinoma, the DNA was interrogated for the presence of TP53 mutations using a method capable of detecting rare mutant alleles in a mixture of mutant and wild-type DNA. RESULTS: Thirty-three patients were enrolled. Eight patients with advanced serous ovarian cancer were included for analysis. Three had a prior tubal ligation. TP53 mutations were identified in all eight tumor samples. Analysis of the DNA from the tampons revealed mutations in three of the five patients with intact tubes (sensitivity 60%) and in none of the three patients with tubal ligation. In all three participants with mutation detected in the tampon specimen, the tumor and the vaginal DNA harbored the exact same TP53 mutation. The fraction of DNA derived from exfoliated tumor cells ranged from 0.01% to 0.07%. CONCLUSION: In this pilot study, DNA derived from tumor was detected in the vaginas of 60% of patients with ovarian cancer with intact fallopian tubes. With further development, this approach may hold promise for the early detection of this deadly disease" |
| Keywords: | "Adult Aged Biomarkers, Tumor/*analysis/genetics Cystadenocarcinoma, Serous/*diagnosis/genetics/surgery DNA Mutational Analysis Early Detection of Cancer Female Humans Menstrual Hygiene Products Middle Aged Neoplasm Grading Ovarian Neoplasms/*diagnosis/gen;" |
| Notes: | "MedlineErickson, Britt K Kinde, Isaac Dobbin, Zachary C Wang, Yuxuan Martin, Jovana Y Alvarez, Ronald D Conner, Michael G Huh, Warner K Roden, Richard B S Kinzler, Kenneth W Papadopoulos, Nickolas Vogelstein, Bert Diaz, Luis A Jr Landen, Charles N Jr eng T32 GM007309/GM/NIGMS NIH HHS/ T32-CA091078/CA/NCI NIH HHS/ 5UL1RR025777/RR/NCRR NIH HHS/ P50 CA098252/CA/NCI NIH HHS/ T32 CA091078/CA/NCI NIH HHS/ UL1 RR025777/RR/NCRR NIH HHS/ T32 CA009515/CA/NCI NIH HHS/ P50CA098252/CA/NCI NIH HHS/ Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2014/12/02 Obstet Gynecol. 2014 Nov; 124(5):881-885. doi: 10.1097/AOG.0000000000000484" |
